[1] Russell MW, Mestecky J, Julian BA, et al.IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli[J]. J Clin Immunol,1986,6(1):74-86.
[2] Moriyama T, Tanaka K, Iwasaki C, et al.Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan[J]. PLoS One,2014,9(3):e91756.
[3] Czerkinsky C, Koopman WJ, Jackson S, et al.Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies[J]. J Clin Invest,1986,77(6):1931-1938.
[4] Boyd JK, Cheung CK, Molyneux K, et al.An update on the pathogenesis and treatment of IgA nephropathy[J]. Kidney Int,2012,81(9):833-843.
[5] Allen AC, Bailey EM, Brenchley PE, et al.Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients[J]. Kidney Int,2001, 60(3):969-973.
[6] Suzuki H, Kiryluk K, Novak J, et al.The pathophysiology of IgA nephropathy[J]. J Am Soc Nephrol,2011,22(10):1795-1803.
[7] Tomana M, Novak J, Julian BA, et al.Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies[J]. J Clin Invest,1999,104(1):73-81.
[8] Eison TM, Hastings MC, Moldoveanu Z, et al.Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy[J]. Clin Nephrol,2012,78(6):465-469.
[9] Endo M, Ohi H, Ohsawa I, et al.Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy[J]. Nephrol Dial Transplant,1998,13(8):1984-1990.
[10] Berthoux F, Suzuki H, Thibaudin L, et al.Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy[J]. J Am Soc Nephrol,2012,23(9):1579-1587.
[11] Watanabe K, Sugai M, Nambu Y, et al.Requirement for Runx proteins in IgA class switching acting downstream of TGF-beta 1 and retinoic acid signaling[J]. J Immunol,2010,184(6):2785-2792.
[12] Launay P, Grossetête B, Arcos-Fajardo M, et al.Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evi-dence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice[J]. J Exp Med,2000, 191(11):1999-2009.
[13] Moldoveanu Z, Wyatt RJ, Lee JY, et al.Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels[J]. Kidney Int,2007,71(11):1148-1154.
[14] Jiang M, Jiang X, Rong L, et al.Serum galactose-deficient IgA1 levels in children with IgA nephropathy[J]. Int J Clin Exp Med,2015,8(5):7861-7866.
[15] Shimozato S, Hiki Y, Odani H, et al.Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy[J]. Nephrol Dial Transplant,2008,23(6):1931-1939.
[16] Berthelot L, Robert T, Vuiblet V, et al.Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes[J]. Kidney Int,2015,88(4):815-822.
[17] Kiryluk K, Moldoveanu Z, Sanders JT, et al.Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis[J]. Kidney Int,2011,80(1):79-87.
[18] Camilla R, Suzuki H, Daprà V, et al.Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy[J]. Clin J Am Soc Nephrol,2011,6(8):1903-1911.
[19] Lau KK, Wyatt RJ, Moldoveanu Z, et al.Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura[J]. Pediatr Nephrol,2007, 22(12):2067-2072.
[20] Hastings MC, Moldoveanu Z, Julian BA, et al.Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability[J]. Clin J Am Soc Nephrol,2010,5(11):2069-2074.
[21] Hastings MC, Afshan S, Sanders JT, et al.Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy[J]. Int J Nephrol,2012,2012:315467.
[22] Berthoux F, Suzuki H, Thibaudin L, et al.Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy[J]. J Am Soc Nephrol,2012,23(9):1579-1587.
[23] Hastings MC, Moldoveanu Z, Julian BA, et al.Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability[J]. Clin J Am Soc Nephrol,2010,5(11):2069-2074.
[24] Zhao N, Hou P, Lv J, et al.The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression[J]. Kidney Int,2012, 82(7):790-796.
[25] Suzuki Y, Matsuzaki K, Suzuki H, et al.Serum levels of galactose-deficient immunoglobulin(Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy[J]. Clin Exp Nephrol,2014,18(5):770-777.
[26] Yanagawa H, Suzuki H, Suzuki Y, et al.A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases[J]. PLoS One,2014,9(5):e98081.
[27] Stuchlová Horynová M, Raška M, Clausen H, et al.Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma[J]. Cell Mol Life Sci,2013,70(5):829-839.
[28] Tissandié E, Morelle W, Berthelot L, et al.Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases[J]. Kidney Int,2011,80(12):1352-1363.
[29] 谢静远, 史曼曼. 原发性IgA肾病危险因素及危险评分研究进展[J]. 内科理论与实践,2016,11(3):156-160.
